InvestorsHub Logo
Followers 62
Posts 24503
Boards Moderated 0
Alias Born 11/23/2016

Re: ALP7 post# 406878

Sunday, 03/12/2023 1:32:58 PM

Sunday, March 12, 2023 1:32:58 PM

Post# of 471241
This is why I am very intrigued to see the KEM analysis that includes before and after poo samples from the: OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001.

Other Outcome Measures:
Microbiota [ Time Frame: 48 weeks ]
Change from baseline to End of Treatment as measured by microbiota


This follows on from these findings: Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference

I believe that similarly microbiota samples are also part of the P2b/3 OLE study.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News